Overview


According to FutureWise analysis, the market for Acute Respiratory Distress Syndrome is expected to grow at a CAGR of 10.30% over the forecast period of 2023-2031.

Acute Respiratory Distress Syndrome (ARDS) is a severe medical condition that affects the lungs. It is characterized by inflammation and fluid accumulation in the lungs' tiny air sacs (alveoli), leading to impaired oxygenation and ventilation. ARDS typically occurs as a response to an underlying injury or illness, such as pneumonia, sepsis, trauma, or inhalation of harmful substances. The development of ARDS involves a complex chain of events. When an injury or infection triggers an inflammatory response, immune cells release various substances, including inflammatory cytokines. These cytokines cause damage to the delicate lung tissue, leading to increased permeability of the alveolar-capillary membrane. As a result, fluid leaks from the capillaries into the alveoli, impairing the exchange of oxygen and carbon dioxide. The fluid accumulation in the lungs further compromises lung function and leads to severe respiratory distress. Patients with ARDS often experience rapid and shallow breathing, severe shortness of breath, low blood oxygen levels, and lung infiltrates visible on imaging tests.

Acute respiratory distress syndrome (ARDS) affects roughly one-third or (33%) of hospitalized patients, according to a study named "Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management," published in the Springer in December 2021. Additionally, of the COVID-19 patients admitted to the intensive care unit, 75% (or nearly 3/4) have ARDS. The prognosis and fatality rate for ARDS patients with COVID-19 are not favorable. As a result, COVID-19 has significantly impacted the market for acute respiratory distress.

FutureWise Market Research has published a report that provides an insightful analysis of Acute Respiratory Distress Syndrome (ARDS) Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes the stature of key manufacturers operational in this industry.

According to the analysis conducted by FutureWise research analysts, Acute Respiratory Distress Syndrome (ARDS) Market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition to providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organization to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base. 

  • Atersys Inc
  • MondoBIOTECh AG
  • HEALIOS K.K.
  • GlaxoSmithKline Plc
  • Pfizer Inc
  • Teva Pharmaceuticals
  • Altor bioScience
  • Faron Pharmaceuticals

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Acute Respiratory Distress Syndrome (ARDS) Market:

  • ExoFlo (DB-001) by Direct Biologics is an extracellular signal product from human bone marrow mesenchymal stem or stromal cells (BM-MSCs). It contains exosomes and growth factors. It provides humans with organic bioactive signals that lower inflammation, direct cellular communication, and accelerate tissue healing. In April 2022, the FDA designated ExoFlo as a Regenerative Medicine Advanced Therapy (RMAT). The company began phase III testing of the ARDS medication for moderate-to-severe COVID-19 ARDS in July 2022.

Globally, the incidence of ARDS is increasing due to aging populations, the prevalence of chronic diseases, and the effects of conditions like sepsis, pneumonia, and trauma. The demand for diagnostic methods, therapeutic choices, and supportive care modalities increases as ARDS cases rise. The early identification and diagnosis of ARDS have improved owing to developments in medical technology and diagnostic methods. Lung ultrasonography and computed tomography (CT) scans offer more precise and prompt detection of ARDS, enhancing management and patient outcomes. ARDS frequently necessitates admission to an intensive care unit (ICU) and specialized care. The rising emphasis on critical care medicine, including advanced ventilation techniques, monitoring tools, and supportive therapies, drives the demand for goods and services related to ARDS management. There were 2,946 non-profit community hospitals in the United States in 2021, according to the American Hospital Association Statistics 2022. This figure increased to 2,960 in 2022 because there are more beds available to treat ARDS patients and more hospitals support segment expansion over the forecast period. Additionally, the surge in acute respiratory distress syndrome is anticipated to result in profitable development for specialty clinics. An increase in hospital admissions to the critical care unit creates the demand for ARDS treatment, which fuels the market's growth. However, ARDS is complex since its underlying causes, clinical symptoms, and disease development patterns vary. Because of the variability, it is challenging to conduct clinical trials, develop standardized treatment strategies, and obtain reliable findings. Developing tailored therapeutics for ARDS requires a consistent approach, which could restrict market growth. Treatment for ARDS can be expensive, especially for individuals who require intensive care and prolonged hospital stays. The cost of supportive care, mechanical ventilation, expert monitoring, medications, and other related charges may significantly impact patients, healthcare systems, and insurers. Access to necessary care may be hampered by the high expense of controlling ARDS, which could limit market growth.

By Drug Class

  • Vasoconstrictors
  • Bronchodilators
  • Steroids and Antibiotics
  • Nitric Oxide
  • Sedatives and Paralytics
  • Surfactant
  • Others

By Route of Administration

  • Oral
  • Injection
  • Inhalation

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022. Due to the existence of major market participants, a rise in product approvals, an advanced healthcare system, and a high frequency of acute respiratory distress syndrome, North America led the global market for ARDS. The frequency of ARDS in the United States is reported to vary from 64.2 to 78.9 instances per 100,000 individuals per year, according to research named "Acute Respiratory Distress Syndrome" which was published in the National Library of Medicine in February 2022. Initial evaluations of ARDS cases place 25% in the mild group and 75% in the moderate or severe group. However, one-third of mild cases progress to become moderate or severe conditions. As a result, the rising prevalence of ARDS in North America promotes market expansion throughout the projection period.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Acute Respiratory Distress Syndrome (ARDS) Market By Drug Class, By Route Of Administration, By Distribution Channel, and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches.

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Acute Respiratory Distress Syndrome Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Acute Respiratory Distress Syndrome Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Acute Respiratory Distress Syndrome Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Acute Respiratory Distress Syndrome Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Vasoconstrictors
        2. Bronchodilators
        3. Steroids and Antibiotics
        4. Nitric Oxide
        5. Sedatives and Paralytics
        6. Surfactant
        7. Others

  • 8.   Acute Respiratory Distress Syndrome Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Oral
        2. Injection
        3. Inhalation

  • 9.   Acute Respiratory Distress Syndrome Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies
        4. Others

  • 10.   North America Acute Respiratory Distress Syndrome Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Acute Respiratory Distress Syndrome Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Acute Respiratory Distress Syndrome Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Acute Respiratory Distress Syndrome Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Acute Respiratory Distress Syndrome Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •   1. Atersys Inc
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. MondoBIOTECh AG
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. HEALIOS K.K.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. GlaxoSmithKline Plc
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Pfizer Inc
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Teva Pharmaceuticals
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Altor bioScience
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Faron Pharmaceuticals
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact

    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

Related Market

Severe Acute Respiratory Syndrome Market

Read More

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11